A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT ID: NCT00236015
Last Updated: 2014-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
880 participants
INTERVENTIONAL
2004-11-30
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236067
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236054
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.
NCT00214994
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
NCT00233675
Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder
NCT00208741
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gabitril
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Have been diagnosed with any other psychiatric Axis I disorder (except GAD) as a principal diagnosis within the past six months
* Have been diagnosed with any eating disorder within the past six months
* Have any history of OCD, psychotic disorder, bipolar disorder or antisocial personality disorder
* Have any history of alcohol or substance abuse within 3 months of screening
* Have any history of seizures, including febrile seizures
* Have any history of head trauma associated with loss of consciousness within the past 15 years
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cephalon
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pivotol Research Centers
Mesa, Arizona, United States
Pivotal Research Center
Peoria, Arizona, United States
Valley Clinical Research
El Centro, California, United States
Radiant Research Irvine
Irvine, California, United States
Pharmacology Research Institute
Los Alamitos, California, United States
Pharmacology Research Institute
Riverside, California, United States
Clinical Innovations, Inc.
Santa Ana, California, United States
Radiant Research
Denver, Colorado, United States
University of Connecticut Health Center
Farmington, Connecticut, United States
Miami Research Associates
Miami, Florida, United States
Medical Research Group of Central Florida
Orange City, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
Roskamp Institute, Clinical Trials Division
Sarasota, Florida, United States
Stedman Clinical Trials
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
American Medical Research
Aurora, Illinois, United States
Henry Lahmeyer MD & Associates
Northfield, Illinois, United States
Midwest Center for Neurobehavioral Medicine
Oakbrook Terrace, Illinois, United States
Indiana University Hospital AOC
Indianapolis, Indiana, United States
Vince & Associates Clinical Research
Overland Park, Kansas, United States
Pedia Research, LLC
Owensboro, Kentucky, United States
Four Rivers Clinical Research
Paducah, Kentucky, United States
LSU Health Science Center
Shreveport, Louisiana, United States
Capital Clinical Research Associates
Rockville, Maryland, United States
Dupont Clinical Research
Rockville, Maryland, United States
Center for Psychopharmacologic Research and Treatment
Worcester, Massachusetts, United States
Wayne State University
Detroit, Michigan, United States
Regions Hospital - Department of Behavioral Health
Saint Paul, Minnesota, United States
Radiant Research
Las Vegas, Nevada, United States
Center for Emotional Fitness
Moorestown, New Jersey, United States
Fieve Clinical Services, Inc.
New York, New York, United States
Behavioral Medical Research of Staten Island
Staten Island, New York, United States
Medark Clinical Trials and Research
Morganton, North Carolina, United States
Richard Weisler, MD and Associates
Raleigh, North Carolina, United States
Wake Research Associates, LLC
Raleigh, North Carolina, United States
Midwest Clinical Research Center
Dayton, Ohio, United States
Pahl Pharmaceutical Research, LLC
Oklahoma City, Oklahoma, United States
Oregon Center for Clinical Investigations, Inc.
Eugene, Oregon, United States
Keystone Clinical Studies, LLC
Norristown, Pennsylvania, United States
CNS Research Institute
Philadelphia, Pennsylvania, United States
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, United States
Future Search Trials
Austin, Texas, United States
Claghorn-Lesem Research Clinic, Inc.
Bellaire, Texas, United States
Mood Disorders Research Clinic; UT Southwestern Medical Center at Dallas
Dallas, Texas, United States
R/D Clinical Research, Inc.
Lake Jackson, Texas, United States
Croft Group Research Center
San Antonio, Texas, United States
University of Utah Mood Disorders Clinic
Salt Lake City, Utah, United States
Dean Foundation
Middleton, Wisconsin, United States
University of Alberta
Edmonton, Alberta, Canada
University of British Columbia, Vancouver
Vancouver, British Columbia, Canada
St. Boniface General Hospital
Winnipeg, Manitoba, Canada
Mood Disorders Clinic
Hamilton, Ontario, Canada
Center for Addiction and Mental Health, Mood and Anxiety Program
Toronto, Ontario, Canada
Clinique Marie-Fitzbach,
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C6671/3030/AX/US
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.